A prodrug of the plant-derived chemotherapeutic substance triptolide, Minnelide, has been shown to inactive CAFs and promote tumor regression in a TGF-β-dependent manner in a preclinical model [31]. This evidence concerns the gene TGFB1 and neoplasm.